| abstract |
The present invention relates to a novel use of arsenic trioxide (Arsenic Trioxide, As 2 O 3 ) compound as a radiotherapy enhancer, and more particularly, the present invention, before irradiating cancer cells to radiation in vivo, Or a new use of As 2 O 3 which can be administered during irradiation to produce a radiotherapy enhancing effect.n n n Since the substance improves the radiation treatment efficiency in cancer tissues, the same effect as the high dose treatment can be obtained while lowering the dose of the radiation treatment, thereby significantly reducing the damage of normal cells, a side effect of high dose radiation treatment. Thus, the efficiency of radiation treatment can be maximized. |